EFFICACY AND SAFETY OF REGDANVIMAB THERAPY IN MODERATE COURSE OF COVID-19
The efficacy and safety of therapy with a human monoclonal antibody (international patent name Regdanvimab) in patients with a moderate course of COVID-19 was evaluated. A total of 41 patients (48.8 % women and 51.2 % men) were treated during the period of mixed distribution of delta and omicron str...
| Main Authors: | , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
The Publishing House Medicine and Enlightenment
2023-02-01
|
| Series: | Medicina v Kuzbasse |
| Subjects: | |
| Online Access: | https://mednauki.ru/index.php/MK/article/view/852 |
| _version_ | 1797832929124024320 |
|---|---|
| author | Михаил Исаакович Ликстанов Ирина Николаевна Кушнир Анна Владимировна Ромасюк Ирина Анатольевна Хмелева Екатерина Александровна Власова Мария Сергеевна Маталасова Татьяна Владимировна Шофорусь Мария Геннадьевна Якушенко Елена Владимировна Стрельцова Павел Аскандерович Аскандеров Вадим Гельевич Мозес Евгения Юрьевна Рисовер Елена Владимировна Рудаева Светлана Ивановна Елгина Кира Борисовна Мозес |
| author_facet | Михаил Исаакович Ликстанов Ирина Николаевна Кушнир Анна Владимировна Ромасюк Ирина Анатольевна Хмелева Екатерина Александровна Власова Мария Сергеевна Маталасова Татьяна Владимировна Шофорусь Мария Геннадьевна Якушенко Елена Владимировна Стрельцова Павел Аскандерович Аскандеров Вадим Гельевич Мозес Евгения Юрьевна Рисовер Елена Владимировна Рудаева Светлана Ивановна Елгина Кира Борисовна Мозес |
| author_sort | Михаил Исаакович Ликстанов |
| collection | DOAJ |
| description | The efficacy and safety of therapy with a human monoclonal antibody (international patent name Regdanvimab) in patients with a moderate course of COVID-19 was evaluated. A total of 41 patients (48.8 % women and 51.2 % men) were treated during the period of mixed distribution of delta and omicron strains of SARS-CoV-2. Regdanvimab was administered in a hospital setting based on the calculation of the amount of 40 mg/kg per patient's body weight. The median dose of regdanvimab was 3200 (2720; 4000) mg, the minimum dose was 2040 mg, and the maximum dose was 4800 mg.
When prescribing regdanvimab, on the second day there was an improvement in the clinical picture and laboratory parameters characterizing the course of the infectious process. The lethality of patients during the study was due to the severity of the course of concomitant diseases and emphasizes the need for an integrated approach to the management of comorbid patients with the involvement of specialists from related fields, such as nephrologists, oncologists, chemotherapists, cardiologists, etc., in prescribing therapy.
Thus, Regdanvimab proved the efficacy and safety of use in patients with COVID-19 during routine practice, while the clinical efficacy of the drug was shown in a mixed cohort of delta-omicron strains. |
| first_indexed | 2024-04-09T14:15:35Z |
| format | Article |
| id | doaj.art-c9c41a07b8ef40329ec7208ab50205fc |
| institution | Directory Open Access Journal |
| issn | 1819-0901 2588-0411 |
| language | Russian |
| last_indexed | 2024-04-09T14:15:35Z |
| publishDate | 2023-02-01 |
| publisher | The Publishing House Medicine and Enlightenment |
| record_format | Article |
| series | Medicina v Kuzbasse |
| spelling | doaj.art-c9c41a07b8ef40329ec7208ab50205fc2023-05-05T11:35:19ZrusThe Publishing House Medicine and EnlightenmentMedicina v Kuzbasse1819-09012588-04112023-02-012211721754EFFICACY AND SAFETY OF REGDANVIMAB THERAPY IN MODERATE COURSE OF COVID-19Михаил Исаакович Ликстанов0Ирина Николаевна Кушнир1Анна Владимировна Ромасюк2Ирина Анатольевна Хмелева3Екатерина Александровна Власова4Мария Сергеевна Маталасова5Татьяна Владимировна Шофорусь6Мария Геннадьевна Якушенко7Елена Владимировна Стрельцова8Павел Аскандерович Аскандеров9Вадим Гельевич Мозес10Евгения Юрьевна Рисовер11Елена Владимировна Рудаева12Светлана Ивановна Елгина13Кира Борисовна Мозес14ГАУЗ КОКБ им. С.В. Беляева, г. КемеровоГАУЗ КОКБ им. С.В. Беляева, г. КемеровоГАУЗ КОКБ им. С.В. Беляева, г. КемеровоГАУЗ КОКБ им. С.В. Беляева, г. КемеровоГАУЗ КОКБ им. С.В. Беляева, г. КемеровоГАУЗ КОКБ им. С.В. Беляева, г. КемеровоГАУЗ КОКБ им. С.В. Беляева, г. КемеровоГАУЗ КОКБ им. С.В. Беляева, г. КемеровоГАУЗ КОКБ им. С.В. Беляева, г. КемеровоГАУЗ КОКБ им. С.В. Беляева, г. КемеровоФГБОУ ВО КемГУ, г. КемеровоКузбасская областная клиническая больница имени С.В. Беляева, г. КемеровоФГБОУ ВО КемГМУ Минздрава России, г. КемеровоФГБОУ ВО КемГМУ Минздрава России, г. КемеровоФГБОУ ВО КемГМУ Минздрава России, г. КемеровоThe efficacy and safety of therapy with a human monoclonal antibody (international patent name Regdanvimab) in patients with a moderate course of COVID-19 was evaluated. A total of 41 patients (48.8 % women and 51.2 % men) were treated during the period of mixed distribution of delta and omicron strains of SARS-CoV-2. Regdanvimab was administered in a hospital setting based on the calculation of the amount of 40 mg/kg per patient's body weight. The median dose of regdanvimab was 3200 (2720; 4000) mg, the minimum dose was 2040 mg, and the maximum dose was 4800 mg. When prescribing regdanvimab, on the second day there was an improvement in the clinical picture and laboratory parameters characterizing the course of the infectious process. The lethality of patients during the study was due to the severity of the course of concomitant diseases and emphasizes the need for an integrated approach to the management of comorbid patients with the involvement of specialists from related fields, such as nephrologists, oncologists, chemotherapists, cardiologists, etc., in prescribing therapy. Thus, Regdanvimab proved the efficacy and safety of use in patients with COVID-19 during routine practice, while the clinical efficacy of the drug was shown in a mixed cohort of delta-omicron strains.https://mednauki.ru/index.php/MK/article/view/852covid-19регданвимаблечение |
| spellingShingle | Михаил Исаакович Ликстанов Ирина Николаевна Кушнир Анна Владимировна Ромасюк Ирина Анатольевна Хмелева Екатерина Александровна Власова Мария Сергеевна Маталасова Татьяна Владимировна Шофорусь Мария Геннадьевна Якушенко Елена Владимировна Стрельцова Павел Аскандерович Аскандеров Вадим Гельевич Мозес Евгения Юрьевна Рисовер Елена Владимировна Рудаева Светлана Ивановна Елгина Кира Борисовна Мозес EFFICACY AND SAFETY OF REGDANVIMAB THERAPY IN MODERATE COURSE OF COVID-19 Medicina v Kuzbasse covid-19 регданвимаб лечение |
| title | EFFICACY AND SAFETY OF REGDANVIMAB THERAPY IN MODERATE COURSE OF COVID-19 |
| title_full | EFFICACY AND SAFETY OF REGDANVIMAB THERAPY IN MODERATE COURSE OF COVID-19 |
| title_fullStr | EFFICACY AND SAFETY OF REGDANVIMAB THERAPY IN MODERATE COURSE OF COVID-19 |
| title_full_unstemmed | EFFICACY AND SAFETY OF REGDANVIMAB THERAPY IN MODERATE COURSE OF COVID-19 |
| title_short | EFFICACY AND SAFETY OF REGDANVIMAB THERAPY IN MODERATE COURSE OF COVID-19 |
| title_sort | efficacy and safety of regdanvimab therapy in moderate course of covid 19 |
| topic | covid-19 регданвимаб лечение |
| url | https://mednauki.ru/index.php/MK/article/view/852 |
| work_keys_str_mv | AT mihailisaakovičlikstanov efficacyandsafetyofregdanvimabtherapyinmoderatecourseofcovid19 AT irinanikolaevnakušnir efficacyandsafetyofregdanvimabtherapyinmoderatecourseofcovid19 AT annavladimirovnaromasûk efficacyandsafetyofregdanvimabtherapyinmoderatecourseofcovid19 AT irinaanatolʹevnahmeleva efficacyandsafetyofregdanvimabtherapyinmoderatecourseofcovid19 AT ekaterinaaleksandrovnavlasova efficacyandsafetyofregdanvimabtherapyinmoderatecourseofcovid19 AT mariâsergeevnamatalasova efficacyandsafetyofregdanvimabtherapyinmoderatecourseofcovid19 AT tatʹânavladimirovnašoforusʹ efficacyandsafetyofregdanvimabtherapyinmoderatecourseofcovid19 AT mariâgennadʹevnaâkušenko efficacyandsafetyofregdanvimabtherapyinmoderatecourseofcovid19 AT elenavladimirovnastrelʹcova efficacyandsafetyofregdanvimabtherapyinmoderatecourseofcovid19 AT pavelaskanderovičaskanderov efficacyandsafetyofregdanvimabtherapyinmoderatecourseofcovid19 AT vadimgelʹevičmozes efficacyandsafetyofregdanvimabtherapyinmoderatecourseofcovid19 AT evgeniâûrʹevnarisover efficacyandsafetyofregdanvimabtherapyinmoderatecourseofcovid19 AT elenavladimirovnarudaeva efficacyandsafetyofregdanvimabtherapyinmoderatecourseofcovid19 AT svetlanaivanovnaelgina efficacyandsafetyofregdanvimabtherapyinmoderatecourseofcovid19 AT kiraborisovnamozes efficacyandsafetyofregdanvimabtherapyinmoderatecourseofcovid19 |